NASDAQ:OKUR OnKure Therapeutics Q1 2026 Earnings Report $4.07 +0.51 (+14.33%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$4.08 +0.01 (+0.37%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OnKure Therapeutics EPS ResultsActual EPS-$1.11Consensus EPS -$0.74Beat/MissMissed by -$0.37One Year Ago EPSN/AOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.17 millionBeat/MissN/AYoY Revenue GrowthN/AOnKure Therapeutics Announcement DetailsQuarterQ1 2026Date5/5/2026TimeBefore Market OpensConference Call DateTuesday, May 5, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) OnKure Therapeutics Earnings HeadlinesContrasting OnKure Therapeutics (NASDAQ:OKUR) & Agios Pharmaceuticals (NASDAQ:AGIO)May 15, 2026 | americanbankingnews.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.com"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and spotted Amazon when it was still considered a bookstore - moves followed by gains of 249,900%, 112,700%, and 216,100%. Now Gilder has identified three companies building a new chip architecture he calls the 'Trillion Dollar Triangle' - one that could make current AI data centers obsolete. One company designed it, one can build it at scale, and a third is preparing to go public. | Eagle Publishing (Ad)OnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function. The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors. OKI-179 is designed to achieve potent antitumor activity while minimizing the off-target toxicities associated with earlier HDAC inhibitors. In parallel, OnKure is developing OKI-272, a reversible Bruton’s tyrosine kinase (BTK) inhibitor targeting B-cell malignancies and autoimmune conditions, with ongoing preclinical and early clinical assessments. Founded by a team experienced in drug discovery and clinical development, OnKure leverages integrated chemistry, biology, and translational science capabilities to move its pipeline forward. The company collaborates with specialized contract research organizations and academic centers to support its clinical programs and accelerate development timelines. OnKure’s management team brings together industry veterans with extensive backgrounds in oncology drug development, clinical operations, and regulatory affairs. The company is committed to advancing its therapeutic candidates through clinical proof-of-concept and toward potential commercialization for patients with high unmet medical needs.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
